Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.66 |
| ▸ | MAP2K2 | P36507 | 12/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536721 | 1.00 | MAP2K1 (0.66) | MAP2K1MAP2K2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL24558569 | 0.90 | MAP2K2 (0.54) | MAP2K1MAP2K2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL24558576 | 0.88 | MAP2K2 (0.52) | MAP2K1MAP2K2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL24558575 | 0.88 | MAP2K2 (0.51) | MAP2K1MAP2K2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31135608 | 0.88 | MAP2K2 (0.51) | MAP2K1MAP2K2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30827551 | 0.85 | MAP2K1 (0.60) | MAP2K1MAP2K2MEN1KMT2A | |
| SCHEMBL24558553 | 0.85 | MAP2K1 (0.60) | MAP2K1MAP2K2MEN1KMT2A | |
| SCHEMBL31135627 | 0.84 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL24558567 | 0.83 | MAP2K1 (0.48) | MAP2K1MAP2K2 | |
| SCHEMBL30827540 | 0.83 | MAP2K1 (0.48) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551073-A | Thienylaniline compounds for the treatment of dermatological disorders | 恩福莱克逊治疗有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230255945-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| WO-2023096935-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFLECTION THERAPEUTICS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113498340-A | Thienylaniline compounds for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2021-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, NAT1, BRAF | MAP2K1 455/4885MAP2K2 282/4885ALDH1A1 176/4885 |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885ALDH1A1 1050/4885 |
| US-20230255945-A1 | FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS | POLR1C, CUTA, POLR2A | MAP2K1 3553/4885MAP2K2 3132/4885ALDH1A1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.